Cantargia: new data from two clinical studies strongly support nadunolimab efficacy after ...
Cantargia reports strong antitumor effects and encouraging median survival times in 55 cancer patients treated with nadunolimab after pembrolizumab. Data suggest nadunolimab targets immunosuppressive cells in the tumor microenvironment, with significant benefits seen in second-line non-squamous patients and heavily pretreated patients. Results to be presented at ESMO Congress 2024.
Related Clinical Trials
Highlighted Terms
Related News
Cantargia reports strong antitumor effects and encouraging median survival times in nadunolimab combination therapy trials involving 55 cancer patients previously treated with pembrolizumab. The data suggest nadunolimab's unique role in targeting immunosuppressive cells in the tumor microenvironment, with results to be presented at ESMO Congress 2024.
Cantargia reports strong antitumor effects and encouraging median survival times in 55 cancer patients treated with nadunolimab after pembrolizumab. Data suggest nadunolimab targets immunosuppressive cells in the tumor microenvironment, to be presented at ESMO Congress 2024.
Cantargia reports strong antitumor effects and encouraging median survival times in 55 cancer patients treated with nadunolimab after pembrolizumab. Data suggest nadunolimab targets immunosuppressive cells in the tumor microenvironment, with significant benefits seen in second-line non-squamous patients and heavily pretreated patients. Results to be presented at ESMO Congress 2024.
New data from two clinical trials in 55 patients show nadunolimab's potential in treating patients who have progressed on pembrolizumab, with a median survival of 19.7 months and a disease control rate of 60%. The trials, CANFOUR and CIRIFOUR, highlight nadunolimab's efficacy in targeting immune suppressive cells in the tumor microenvironment.